Last $212.63 USD
Change Today +0.45 / 0.21%
Volume 3.4M
AGN On Other Exchanges
New York
As of 8:04 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

allergan inc (AGN) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/5/14 - $214.66
52 Week Low
12/23/13 - $106.26
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ALLERGAN INC (AGN)

allergan inc (AGN) Details

Allergan, Inc. operates as a multi-specialty health care company primarily in the United States, Europe, Latin America, and the Asia Pacific. The company discovers, develops, and commercializes pharmaceutical, biological, medical device, and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological, and other specialty markets. It operates in two segments, Specialty Pharmaceuticals and Medical Devices. The Specialty Pharmaceuticals segment produces a range of pharmaceutical products, including ophthalmic products for dry eye, glaucoma, inflammation, infection, allergy, and retinal disease; Botox for certain therapeutic and aesthetic indications; skin care products for acne, psoriasis, eyelash growth, and other prescription and physician-dispensed skin care products; and urologics products. The Medical Devices segment offers a range of medical devices, such as breast implants for augmentation, revision, and reconstructive surgery, as well as tissue expanders; and facial aesthetics products. The company also holds LiRIS Program, which is in Phase II trials for the treatment of interstitial cystitis/bladder pain syndrome. It sells its products to drug wholesalers, independent and chain drug stores, pharmacies, commercial optical chains, opticians, mass merchandisers, food stores, hospitals, group purchasing organizations, integrated direct hospital networks, ambulatory surgery centers, government purchasing agencies, and medical practitioners. The company focuses on eye care professionals, neurologists, physiatrists, dermatologists, plastic and reconstructive surgeons, aesthetic specialty physicians, urologists, urogynecologists, and general practitioners. It has collaboration agreements with Molecular Partners AG; Spectrum Pharmaceuticals, Inc.; and Serenity Pharmaceuticals, LLC. Allergan, Inc. was founded in 1948 and is headquartered in Irvine, California.

11,500 Employees
Last Reported Date: 11/5/14
Founded in 1948

allergan inc (AGN) Top Compensated Officers

Chairman and Chief Executive Officer
Total Annual Compensation: $1.4M
Total Annual Compensation: $651.9K
Corporate Vice President and President of Nor...
Total Annual Compensation: $550.7K
Chief Scientific Officer and Executive Vice P...
Total Annual Compensation: $642.1K
Non-Executive Officer
Total Annual Compensation: $641.5K
Compensation as of Fiscal Year 2013.

allergan inc (AGN) Key Developments

Shareholders Claim Allergan Inc.'s Board of Directors Adopted Poison Pill to Avoid Acquisition

The shareholders in Allergan Inc. filed a lawsuit alleging the company's board of directors failed to properly consider a buyout offer of the company by Valeant Pharmaceuticals International Inc. and Pershing Square. The plaintiffs allege the proposed acquisition would have been worth up to $59 billion to Allergan shareholders. The complaint claims the defendants ignored the advice of Goldman Sachs, the company's investment banker, to investigate the offer and, instead, adopted bylaw provisions to entrench themselves in the company and protect their own interests. Valeant and Pershing Square also filed a counterclaim against Allergan, alleging the company's tactic of seeking to ward off an acquisition by soliciting opposition from their shareholders without filing a proxy statement violates federal securities law. The complaint alleges the defendants engaged in self-dealing and names several Allergan directors, as well as David E.I. Pyott, the board's chairman and the company's CEO, as defendants.

Actavis plc, Allergan Inc. - M&A Call

To discuss the acquisition of Allergan by Actavis

Fda Approves New Styles of Allergan Inc.'s Natrelle 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants

Allergan Inc. announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market two new styles, X and L, of the Natrelle(R) 410 Highly Cohesive Anatomically Shaped Silicone-Filled Breast Implants for use in breast reconstruction, augmentation and revision surgery. The Natrelle(R) 410 X and L styles provide surgeons additional options to customize their patients' fit by matching the implant's height and width with the patient's body type while providing optimal projection, based on the desired aesthetic outcome. The new Natrelle(R) 410 X styles provide extra full projection, while the new L styles feature low height and low projection. The entire line of Natrelle(R) 410 shaped gel implants are designed to mimic the slope of the breast and are filled with a highly cohesive silicone gel, which is intended to enable the implants to hold their shape over time while remaining soft to the touch. The FDA approval of the additional Natrelle(R) 410 shaped gel implant styles is based on 10-year data from a study of nearly 1,000 women who underwent breast reconstruction, augmentation or revision surgery with the previously approved range of Natrelle(R) 410 breast implants. Natrelle(R) 410 breast implants are the most selected shaped gel implants in the United States and are one of the most extensively studied shaped gel implants.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AGN:US $212.63 USD +0.45

AGN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actavis plc $265.39 USD +1.64
Astellas Pharma Inc ¥1,703 JPY +47.50
Medtronic Inc $74.62 USD -0.01
Regeneron Pharmaceuticals Inc $427.64 USD +3.85
Shire PLC 4,629 GBp -53.00
View Industry Companies

Industry Analysis


Industry Average

Valuation AGN Industry Range
Price/Earnings 49.6x
Price/Sales 9.0x
Price/Book 8.9x
Price/Cash Flow 44.8x
TEV/Sales 8.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALLERGAN INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at